Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 32 min ago
Peer-reviewedCC BY-NC-NDBMC health services research

Research engagement of rare disease patient advocacy groups in Poland: between participation and constrained co-production.

  1. 1Department of Social Sciences and Humanities, Poznan University of Medical Sciences, Rokietnicka 7, Poznan, 60-806 , Poland. [email protected].
  2. 2Department of Organisation and Management in Health Care, Poznan University of Medical Sciences, Poznan, Poland.

Abstract

Background

Rare diseases (RDs) present complex challenges, including diagnostic uncertainty, limited treatment options, and fragmented research and care systems. These constraints contribute to inequities in access to care, information, and research participation among patients and caregivers across social and institutional contexts. In this setting, rare disease patient advocacy groups (RDPAGs) have emerged as key actors, not only providing support to patients and caregivers but also increasingly engaging in research. However, empirical evidence regarding their research engagement and organisational capacities remains limited, particularly in Central and Eastern Europe. This study examines the engagement of RDPAGs in research and intersectoral collaboration in Poland.Methods

A cross-sectional survey was conducted between January and April 2026 among representatives of 64 Polish RDPAGs using a structured, web-based questionnaire. The questionnaire covered organisational characteristics, research engagement, collaboration, and perceived barriers. Data were analysed using descriptive statistics.Results

Most RDPAGs reported at least occasional engagement in research, although involvement was heterogeneous and often limited in scope. RDPAGs were primarily active in non-clinical research domains, including social research, patient registries, and dissemination of research findings. Participation in clinical and translational research was less frequent and largely supportive, particularly in recruitment and patient support. A majority of RDPAGs did not initiate research activities, and only a small proportion reported high levels of engagement. Key barriers included a lack of funding, limited human resources, and restricted influence on research processes. Despite these constraints, collaboration with physicians was common, although often informal. The findings indicate that RDPAGs function as intermediary actors and knowledge brokers, partially compensating for structural gaps in healthcare and research systems by facilitating access to information, support, and research participation for patients and caregivers. The findings further suggest a model of constrained co-production, in which RDPAGs participate in research but remain insufficiently integrated into research decision-making and knowledge production.Conclusions

RDPAGs play an important but structurally constrained role in research and knowledge co-production. Strengthening their contribution requires formalised collaboration frameworks, improved access to resources, capacity-building initiatives, and earlier and more meaningful involvement across the research cycle. Enhancing their role may contribute to more inclusive and effective research systems in the rare disease field.Clinical trial number

Not applicable.

Related

  1. Co-creation in research, policy engagement and advocacy: Lessons and limits from two decades of practice at the African Population and Health Research Center
    Emmanuel Oloche Otukpa, Abdhalah K. Ziraba, Luchuo Engelbert Bain
    PLOS Global Public HealthPeer-reviewedCC BY 4.0Full textEpidemiology & public healthNutritionPLOS
  2. Parental perceptions of children’s physical activity participation: An exploration of satisfaction, school-based engagement, barriers to participation and preferred strategies for improvement
    Chidiebele Petronilla Ojukwu, Okolo Chukwunonyelum Judith, Adaeze Imelda Onyekwelu +3
    PLOS OnePeer-reviewedCC BY 4.0Full textEpidemiology & public healthPLOS
  3. Development of a Children and Young People's Informed Framework for the Design, Delivery and Evaluation of a Patient and Public Involvement, Engagement and Participation Group: A Service Development Project.
    J. Chudleigh, G. Jones, L. Pickard +7
    medRxivPreprintCC BYFull textObstetrics, gynaecology & paediatricsmedRxiv
  4. Parent and child experiences of research participation and retention intentions in a Japanese birth cohort: insights from the Japan Environment and Children’s Study (JECS)
    Tomoko Okabe, Yoshimitsu Takahashi, Mayumi Toyama +5
    Environmental Health and Preventive MedicinePeer-reviewedCC BY 4.0Full text1 citedEpidemiology & public healthJ-STAGE
  5. A novel, free regional conference model to increase interest and engagement of medical trainees in pediatrics and pediatric gastroenterology research
    Mahnoor Memon, Shahzaib Khan, Christina Guillen +1
    JPGN reportsPeer-reviewedCC BYFull textGeneral medicineEurope PMC
BibTeX
@article{domaradzki2026research,
  title = {{Research engagement of rare disease patient advocacy groups in Poland: between participation and constrained co-production.}},
  author = {Jan Domaradzki and Dariusz Walkowiak},
  journal = {BMC health services research},
  year = {2026},
  month = jul,
  doi = {10.1186/s12913-026-15202-w},
  url = {https://europepmc.org/article/MED/42897645},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Research engagement of rare disease patient advocacy groups in Poland: between participation and constrained co-production.
AU  - Jan Domaradzki
AU  - Dariusz Walkowiak
PY  - 2026
DA  - 2026/07/01
JO  - BMC health services research
DO  - 10.1186/s12913-026-15202-w
UR  - https://europepmc.org/article/MED/42897645
AB  - Background  Rare diseases (RDs) present complex challenges, including diagnostic uncertainty, limited treatment options, and fragmented research and care systems. These constraints contribute to inequities in access to care, information, and research participation among patients and caregivers across social and institutional contexts. In this setting, rare disease patient advocacy groups (RDPAGs) have emerged as key actors, not only providing support to patients and caregivers but also increasingly engaging in research. However, empirical evidence regarding their research engagement and organisational capacities remains limited, particularly in Central and Eastern Europe. This study examines the engagement of RDPAGs in research and intersectoral collaboration in Poland.Methods  A cross-sectional survey was conducted between January and April 2026 among representatives of 64 Polish RDPAGs using a structured, web-based questionnaire. The questionnaire covered organisational characteristics, research engagement, collaboration, and perceived barriers. Data were analysed using descriptive statistics.Results  Most RDPAGs reported at least occasional engagement in research, although involvement was heterogeneous and often limited in scope. RDPAGs were primarily active in non-clinical research domains, including social research, patient registries, and dissemination of research findings. Participation in clinical and translational research was less frequent and largely supportive, particularly in recruitment and patient support. A majority of RDPAGs did not initiate research activities, and only a small proportion reported high levels of engagement. Key barriers included a lack of funding, limited human resources, and restricted influence on research processes. Despite these constraints, collaboration with physicians was common, although often informal. The findings indicate that RDPAGs function as intermediary actors and knowledge brokers, partially compensating for structural gaps in healthcare and research systems by facilitating access to information, support, and research participation for patients and caregivers. The findings further suggest a model of constrained co-production, in which RDPAGs participate in research but remain insufficiently integrated into research decision-making and knowledge production.Conclusions  RDPAGs play an important but structurally constrained role in research and knowledge co-production. Strengthening their contribution requires formalised collaboration frameworks, improved access to resources, capacity-building initiatives, and earlier and more meaningful involvement across the research cycle. Enhancing their role may contribute to more inclusive and effective research systems in the rare disease field.Clinical trial number  Not applicable.
SN  - 1472-6963
ER  -